A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome
Status:
Not yet recruiting
Trial end date:
2026-09-28
Target enrollment:
Participant gender:
Summary
This study is open to people with a skin disease called Netherton syndrome (NS). People can
join the study if they are 12 years and older. The purpose of this study is to find out
whether a medicine called spesolimab helps people with NS.
Participants are divided into a spesolimab and a placebo group. Placebo injections look like
spesolimab injections but do not contain any medicine. Every participant has a 2 in 3 chance
of being in the spesolimab group. In the beginning, participants get the study medicine as an
injection into a vein. Afterwards, they get it as an injection under the skin every month.
After 4 months, participants in the placebo group switch to spesolimab treatment.
Participants are in the study for about 1 year. During this time, they visit the study site
16 times. Where possible, 4 of 16 visits can be done at the participant's home instead of the
study site. The doctors regularly check participants' NS symptoms. The results are compared
between the groups to see whether spesolimab works. The doctors also regularly check
participants' general health and take note of any unwanted effects.